North America Powers Global Flow Cytometry Market

In the somewhat consolidated global flow cytometry market, the top three companies accounted for a substantial 50.0 percent in 2016. Their names are Dickinson and Company (BD), Beckman Coulter, Inc. (Danaher), and Becton, Merck and Co., Inc. The players have banked majorly on product development to establish a solid stronghold over the market. Savvy players are expending considerable sums on building superior products such as those outfitted with infrared and ultraviolet sensors. To increase their share in the market, such players are not just adding to their product portfolios but also trying to expand geographical outreach by entering into partnerships and acquisitions.

The global market for flow cytometry will likely rise at a healthy CAGR of 11 percent during 2017–2025. Rising at this pace, the market’s estimated valuation would reach USD 8100 million by 2025. Depending upon the type of product and service, the segment of flow cytometry instruments accounts for a leading market share and in the near future too is expected to hold on to it owing the usage of advanced models for target-based drug discovery. Coming to the geographical segments, North America holds a considerable share in the market. This is primarily because of the rising research and development initiatives by the government in the region. The US is said to be mainly powering the North America market.

Flow cytometry is a commonly used laser-based technology that finds application in analyzing characteristics of particles or cells. It also finds usage in protein engineering, cell sorting, biomarker detection, and cell analysis. Adds the lead analyst of our report, “On account of the speed and ability of flow cytometry to examine the single-cell level, it empowers a biologist to swiftly study and characterize a multitude of cells.” It finds usage in detecting and measuring protein expression, protein post translational modification, RNA, cell health status, cell cycle status, and others. Mainly serving to drive demand for flow cytometry is its usage in detecting systemic ailments. Apart from that, rising instances of various chronic ailments such as cancer and immunological diseases such as AIDS or HIV, alongside hematological diseases has also pushed up demand in the market.

“A growing number of doctors these days prefer autologous and allergenic stem cell therapies instead of radiation and chemotherapy. This is one of the factors driving the uptake of flow cytometers.” explains our lead analyst. Rising investment in research and development is also predicted to positively impact the market for flow cytometry. One difficulty staring at the market, on the other hand, is the emergence and soaring popularity of substitutes such as image and scanning cytometers. Limited awareness about the product is also having a negative impact. – Transparency Market Research